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Abstract The HIV vaccines tested in the halted Step
efficacy trial and the modestly successful phase 3 RV144
trial were designed to elicit strong systemic immune
responses; therefore, strategies to direct immune responses
into mucosal sites should be tested in an effort to improve
AIDS vaccine efficacy. However, as increased CD4
+ T-cell
activation and recruitment to mucosal sites have the
potential to enhance HIV transmission, mucosal immune
responses to HIV vaccines should primarily consist of
effector CD8
+ T cells and plasma cells. Controlling the
level of mucosal T-cell activation may be a critical factor in
developing an effective mucosal AIDS vaccine. Immuniza-
tion routes and adjuvants that can boost antiviral immunity
in mucosal surfaces offer a reasonable opportunity to
improve AIDS vaccine efficacy. Nonhuman primate models
offer the best system for preclinical evaluation of these
approaches.
Keywords HIV.Femalegenitaltract.Immuneactivation.
SIV
Introduction
The recent inability to complete the efficacy trial of an
AIDS vaccine designed to elicit systemic T-cell responses
[1–3] and the modest success in a human phase 3 trial of a
second AIDS vaccine designed to elicit both systemic
antiviral T-cell and antibody responses [4••] highlight the
need for AIDS vaccines that induce antiviral immunity at
mucosal surfaces that are the portal of entry for HIV. The
mucosal immune system represents a highly compartmen-
talized immunological system that in many ways functions
independently from the systemic immune system, although
the systems do interact. The mucosal immune system is a
specialized subset of lymphoid tissues and cells that
preferentially reside within the wide variety of mucosal
surfaces [5–7]. Along with the skin, these mucosal surfaces
form the primary barrier between pathogens and the
vertebrate host. Thus, the mucosal immune system is the
first line of immunologic recognition and defense against
the vast majority of microbial pathogens, including HIV. As
with the systemic immune system, distinguishing self from
nonself antigens is a critical feature of the mucosal immune
system. However, a further challenge exists at mucosal
surfaces, as they are populated with a large number of
beneficial microorganisms. Thus, to maintain a normal
mucosal flora, it is critical that the mucosal system is able
to promote immune recognition of pathogens and maintain
immune tolerance to commensal organisms [5–7].
The nature of the antigen, the specific antigen-presenting
cells (APCs) involved, and the presence of inflammation in
the tissue shape mucosal immune responses. With most
antigens (eg, food proteins), the “default” pathway for
mucosal dendritic cells (DCs) and other APCs generates T
helper 2 (TH2) and regulatory T-cell responses that result in
active suppression of systemic immunity or “oral tolerance”
to food antigens [6]. Pathogens are recognized by mucosal
APCs detecting pathogen-associated molecular patterns that
bind to Toll-like receptors (TLRs), initiating innate immune
and inflammatory responses. Proinflammatory conditions
favor the development of stronger and broader immune
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responses [6]. Although it had been widely assumed that
the commensal microbes were not recognized by the TLRs
of mucosal APCs, microbial commensals are indeed
recognized by TLRs under normal conditions, and this
helps maintain epithelial homeostasis in the gut [6].
B and T cells, sensitized to antigen in mucosal inductive
sites, leave the site of antigen presentation in the mucosa,
move through the lymphatics to enter the blood to recirculate
and re-enter mucosal tissues. The majority of these cells re-
enter the mucosa of origin, where they differentiate into
memory or effector lymphocytes [5, 6]. The anatomic
localization of mucosal lymphocytes is determined by
expression of homing receptors (integrins) on their surface
and complementary mucosal “addressins” on vascular
endothelial cells [5, 6]. Additionally, mucosal DCs influence
the homing properties of mucosal T cells. Intestinal DCs
produce retinoic acid, which increases the expression of the
mucosal-homing receptor α4β7 and CCR9, the receptor for
the gut-associated chemokine CCL25 [5, 6].
Taken together, these observations may explain the
somewhat archaic notion of a “common mucosal immune
system” [5, 6]. Although early studies in mice suggested that
the mucosal surfaces share a common set of mucosal
lymphocytes and that immune responses induced at one site
disseminate to all mucosal surfaces, the common mucosal
immune system is more restricted than previously thought
[5, 6]. In humans, immunization studies with cholera toxin B
subunit by different mucosal routes have clearly shown that
the strongest response takes place at the immunized mucosa,
with weaker responses at anatomically adjacent mucosal
sites [5]. The differential expression of chemokines, integ-
rins, and cytokines among mucosal tissues may explain the
linkage between some mucosal inductive sites and particular
distal effector sites (eg, the nose and female genital tract) [5].
Mucosal HIV Transmission
HIV is transmitted primarily by sexual contact, and the
female genital tract, male genital tract, and rectum are the
anatomic sites of virus transmission [8]. Nonhuman primate
(NHP) models have been critical for understanding how the
virus enters these mucosal surfaces, infects target cells, and
disseminates from mucosal surfaces [9, 10]. HIV and
simian immunodeficiency virus (SIV) rapidly penetrate
the mucus covering the epithelial surface of the vagina
and ectocervix and infect intraepithelial dendritic Langer-
hans cells and CD4
+ T cells in the epithelium and lamina
propria [11]. These infected cells enter draining lymphatics
and can be found in the lymph nodes of the genital tract 18
to 24 h after exposure [11]. However, there is a little
detectable viral replication in tissues until 5 days after
infection, when there are simultaneous and dramatic
increases in viral replication and innate antiviral immune
responses (Type 1 interferon expression) in all tissues [9,
12]. Further, recent studies have conclusively demonstrated
that immediately after mucosal transmission, many system-
ic HIVand many systemic SIV infections are established by
a very limited number (1 or 2) of viral envelope
glycoprotein variants [13, 14•]. Thus, vaccine-induced
immune responses may only need to prevent infection or
replication of a small number of virions transmitted during
an exposure. Importantly, although the virus that establishes
the systemic infection is more fit than chronic phase virus,
acute phase virus is extremely sensitive to neutralization by
chronic phase plasma, suggesting that transmitted virus
could be similarly sensitive to vaccine-induced antibody
responses [15]. Thus, there is a period between mucosal
transmission and the onset of massive viral replication at
day 5 postinfection that may provide an opportunity for
vaccine-induced immune responses to limit or even
eliminate a nascent HIV infection established by a limited
number of viral variants before an infection becomes
established in systemic lymphoid tissues.
Engaging the Mucosal Immune System to Prevent HIV
Transmission
Vaccine-elicited antiviral effector mechanisms of the mucosal
immune system have the potential to provide three layers of
protection from mucosal-transmitted pathogens, such as HIV:
1) dimeric secretory IgA and monomeric IgG and IgA in
mucosal secretions can neutralize virions in the lumen prior to
binding to target cells; 2) dimeric IgA can neutralize virions
inside epithelial cells, and monomeric IgG and IgA can
neutralize virions in the lamina propria; and, 3) virus-infected
cells in the mucosa can be killed by mucosal cytotoxic T cells
and by virus-specific IgG mediating antibody-dependent cell-
mediated cytotoxicity. If any invading virus should overcome
these mucosal immune effector mechanisms, then the vaccine-
elicited systemic immune responses provide a final opportunity
to eliminate HIV infection during the dissemination phase of
infection. However, oncean HIVinfection becomesestablished
in systemic lymphoid tissues, the best outcome that can be
expected is enhanced immune control of viral replication.
To generate mucosal immune responses to HIV vac-
cines, two general strategies are available. Adjuvants can be
used to stimulate the mucosal immune system, and specific
routes of immunization can be used to direct immune
responses toward specific mucosal surfaces. Mucosal
immunization strategies, using either novel adjuvants
codelivered with antigens or replication-defective viral
vectors, represent an important next step in the develop-
ment of improved AIDS vaccines. In fact, it seems likely
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Step HIV vaccine trials could be improved by incorporating
one or both of these strategies to induce antiviral immunity
of mucosal surfaces. NHPs are critical in the effort to
develop these strategies, as they are the only species that
express the appropriate mucosal T-cell homing receptors
and vascular addressins for modeling human mucosal
immune responses to vaccines.
Mucosal Challenge Models for AIDS Vaccines
A number of challenge models exist for assessing the
protective potential of candidate AIDS vaccines, including
NHP models using either SIV or laboratory-engineered
chimeric SIV/HIV (SHIV) viruses. Although the chimeric
SHIVs do not adequately reproduce AIDS pathogenesis and
are not adequate to assess the ability of a candidate vaccine
to alter disease progression, they are adequate to determine
if a vaccine increases resistance to acquiring infection. The
SIV models are excellent models of AIDS pathogenesis and
can be used to assess the effect of vaccination on both
resistance to acquiring infection and the rate of disease
progression in immunized animals that become infected.
Mucosal SIV challenge faithfully reproduces the key
features of mucosal HIV transmission, including the
transmission of a few variants from complex quasispecies
of viral variants [13, 14•]. In addition, NHP models can
employ either a repeated low-dose virus challenge system
or a single high-dose challenge system to meet the specific
objectives of the experiment. NHP SHIV models of
mucosal HIV transmission have been used to demonstrate
that passive transfer of neutralizing monoclonal antibodies
can prevent virus transmission [16], providing support for
the concept that vaccine-elicited antibody responses can
prevent transmission. Recently, a small animal model of
HIV transmission was developed by transplanting human
bone marrow, liver, and thymus (BLT) into severe
combined immunodeficient mice [17]. Consequently, hu-
man APCs and lymphocytes populate the mucosal surfaces,
and the model can be used to assess some strategies to
prevent vaginal HIV transmission [18]. Further, once
infected, the BLT mice generate humoral and cellular
HIV-specific immune responses [19]. However, because
TLR ligands are expressed on a different set of murine cells
compared with human cells, it will be difficult to evaluate
the utility of vaccines and adjuvants that elicit innate
immunity in the BLT mouse. In addition, the existence of a
common mucosal immune system in mice but not in
humans is due to fundamental differences in the distribution
of vascular addressins in mice and humans. Finally, murine
mucosal immune responses do not reflect mucosal immune
responses in NHPs or humans [6].
Review of NHP Mucosal AIDS Vaccine Studies
Although studying mucosal immunity is technically chal-
lenging due to difficulty in obtaining samples of sufficient
quality and quantity for analysis, the need to improve the
relatively low efficacy of the systemic AIDS vaccines
currently in development demands a focus on eliciting
mucosal immune responses through vaccination. Thus,
there is a renewed effort to study mucosal immunology in
preclinical studies of AIDS vaccines. The remainder of this
review summarizes some recently published NHP studies
using a mucosal route of virus challenge. The decision to
focus primarily on the results of mucosal challenge studies
is based on the fact that correlates of protection against HIV
are unknown and thus, immunogenicity studies provide
little insight into the protective potential of the candidate
HIV vaccines [20]. Only studies with mucosal virus
challenge provide an opportunity to assess the potential
immune correlates of protection from mucosal challenge. In
fact, NHP mucosal challenge studies [21] predicted the lack
of immunogenicity and partial efficacy seen in the RV144
phase 3 trial of an ALVAC (recombinant canarypox vector)-
based HIV vaccine in Thailand [4••]. Critically, these
preclinical studies of ALVAC-based vaccines studies used
an appropriate NHP model and repeated low-dose mucosal
challenge with highly pathogenic SIVmac251. Clearly, a
similar approach to preclinical evaluation of HIV candidate
vaccines should be used going forward.
Considerable literature documents the efforts of numer-
ous investigators to elicit anti-SIV/SHIV mucosal immunity
in NHP models. NHP have been immunized with recom-
binant SIV proteins or peptides, live-attenuated SIV or
SHIV, viral or bacterial vectors encoding SIV genes, and
DNA vaccines; this literature up to 2004 was summarized
in the introduction of an article by Yoshino et al. [22]. An
excellent review of more recent NHP mucosal AIDS
vaccine studies was published earlier this year [23••]. In
this article, we focus on some of the NHP AIDS vaccine
studies with mucosal virus challenges published from 2007
to 2009, which are summarized in Tables 1 and 2. Of the 12
articles using mucosal immunization routes, animals were
immunized by the intranasal (IN) route in five articles, by
the tonsillar route in four, by the intratracheal route in two,
and by the rectal route in one (Table 1). Further, two articles
used what was described as oral immunization, but the
immunization actually consisted of placing enteric-coated
capsules containing live Ad5 vectors into the stomach using
gastric feeding tube (Table 1). Although IN immunization
has been studied extensively, it is unlikely to ever be used
clinically, as IN immunization in humans is rarely associ-
ated with onset of Bell’s Palsy [6]. Of the nine articles
using systemic immunization routes, the animals were
immunized by the intramuscular route in six articles, by
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route in two, and by the transdermal route in one (Table 2).
Among the 21 articles reviewed, the vaccinated animals
were challenged by intrarectal (IR) inoculation in 15
articles, by intravaginal (IVAG) inoculation in three, by
tonsil inoculation in two, and by oral virus inoculation in
one (Tables 1 and 2). Of the 12 articles utilizing mucosal
immunization routes, complete protection from, or in-
creased resistance to, infection was reported in three articles
[24–26] (Table 1). This includes two articles reporting
protection from IR challenge with highly pathogenic
SIVmac239 and one from IVAG challenge with variably
pathogenic SHIV162P4. The animals in these three articles
were immunized with various viral antigens, but all three
Table 1 Summary of recent (2007–2009) prophylactic AIDS vaccine studies employing mucosal immunization and mucosal virus challenge in
NHP models
a
Study Vaccine Vaccine route Challenge/
route
Level of protection Immune correlates
Vagenas et al.
[25]
AT-2 SIV + CpG-C Palatine/lingual
tonsils
SIVmac239/
IR
Lower frequency of
infection; lower peak
plasma vRNA levels
Antiviral Ab in rectal
secretions
Copeland [34] Prime SIV + IL-2 + IL-15
DNA/boost SIV–MVA
IN or IM SIVmac251/
IR
CD4 T-cell
preservation and
delayed disease
Systemic and colorectal
T-cell responses
Manrique
et al. [35]
Prime multigenic DNA/
boost MVA adjuvanted by
IL-12 DNA
IN/IN; IM + IN/IM
+ IN or IM/IN
SHIV89.6P/
IR
Lower peak/set point
plasma vRNA
levels; no AIDS
progression
SHIV-specific T-cell
responses in blood
Falkensammer
et al. [36]
SCIV/-SIV genes / Ad5-SIV
or SCIV-MULV env boost
Tonsils SIVmac239/
tonsil
Lower peak/set point
plasma vRNA levels
Neutralizing Ab;
complement C3-deposition
on viral particles in plasma
Stahl-Hennig
et al. [37]
Prime-boost regimen of
SCIV and adenoviral
vector vaccines
Tonsils SIVmac239/
tonsil
lower plasma vRNA
levels
Strong T cell and antibody
responses in blood
Bogers et al.
[38]
Prime Ad5hr-HIV-1 (89.6p)
env/boost heterologous
Env protein or alphavirus
replicons
IN + IT/IM SHIVSF162p4/
IR
Lower plasma vRNA
levels
Titer of neutralizing
antibodies in sera
Hidajat et al.
[39]
Prime Ad5hr-SIV with
env-gag- nef/boost SIV
gp120 protein
(MPL-SE adjuvant)
Oral (tablets +
stomach tube) +
oral or IN + oral/
IM+ IM
SIVmac251/
IR
Lower peak plasma
vRNA levels
ADCVI activity and
transcytosis inhibition
activity in plasma
Demberg
et al. [40]
Prime Ad5hr-SIV DNA ±
IL-12 or IL-15/boost with
SIV gp140 + SIV nef
protein
IM+IT/IM SIVmac251/
IR
No protection None
Zhou et al.
[41]
Prime Ad5 with SIVenv/rev,
gag, and nef genes/boost
with SIV gp120 protein
Oral (tablets +
stomach tube) +
oral or IN + oral/
IM+ IM
SIVmac251/
IR
Lower peak/setpoint
plasma vRNA levels
T cell responses to Gag and
Nef
Stolte-Leeb
et al. [42]
Prime multigenic DNA/
boost MVA
ID/IM-ID + IM-ID
or IM-ID +
palatine tonsils
SHIV89.6P/
IR
Lower peak/setpoint
plasma vRNA
levels; CD4
+ T-cell
preservation
None (better protection from
mucosal and systemic than
systemic vaccination
alone)
Barnett et al.
[26]
HIV-1 SF162 envelope
protein vaccine
IM/IM or IM/IN SHIVSF162p4/
IVAG
Protected from
infection
Serum-neutralizing
antibodies
Wang et al.
[24]
HSP70 + SIVgp120 +
SIVp27 + CCR5; HSP70
+ SIVgp120 + SIVp27;
HSP70 + CCR5
Rectal SIVmac251/
IR
6/15 protected from
infection
Increased A3G mRNA in the
CD4
+CCR5
+ blood and
lymph node T cells
Ab antibody; ADCVI antibody-dependent cell-mediated viral inhibition; Env envelope; Gag group-specific antigen; HSP heat shock protein;
ID intradermal; IL interleukin; IM intramuscular; IN intranasal; IR intrarectal; IT intratracheal; IVAG intravaginal; MPL-SE monophosphoril lipid A
stable emulsion; MULV Moloney murine leukemia virus; MVA modified vaccinia virus Ankara; Nef negative factor; SCIV single-cycle viral vectors;
SF San Francisco; SHIV simian-human immunodeficiency virus; SIV simian immunodeficiency virus; vRNA viral RNA
aDoes not include live-attenuated virus studies
22 Curr HIV/AIDS Rep (2010) 7:19–27vaccines included the viral envelope. However, there was
no commonality in the immunization routes in these three
studies, as either rectal, IN, or tonsillar immunization
routes were used. In two of these three articles, the route
of immunization and challenge was matched [24, 25].
Although many of the other mucosally administered
vaccines decreased viral replication after immunized ani-
mals became infected, none could block infection (Table 1).
Of the nine articles utilizing systemic immunization
routes, complete protection from, or increased resistance to,
infection was reported in one article (Table 2). This article
reported increased resistance to IR challenge with a highly
pathogenic SIVmac239 and used subQ immunization with
a replication competent cytomegalovirus (CMV) vector
expressing multiple SIV antigens, including envelope.
Although the vaccine increased resistance to rectal SIV
challenge, virus replication in immunized animals that
became infected was not altered [27]. The immunologic
basis for the all-or-none protection phenomena seen in this
study remains to be defined, but the results are similar to
the all-or-none protection seen in both recently completed
human AIDS vaccine efficacy trials [1–3, 4••]. Although
the CMV vector was systemically administered, it is a
replicating viral vector that disseminates throughout the
body and produces antigen continuously, albeit at a low
level, in mucosal tissues. Thus, it may not be surprising that
the only study reporting protection from mucosal challenge
after systemic immunization used a replicating viral vector
as a vaccine [27]. Although many of the other systemically
administered vaccines decreased viral replication after
immunized animals became infected, none could block
infection (Table 2).
Lessons from Live-Attenuated AIDS Vaccine Models
We recently completed a series of studies that defined
antiviral T-cell responses in the mucosal and systemic
Table 2 Summary of recent (2007–2009) prophylactic AIDS vaccine studies employing systemic immunization and mucosal virus challenge in
NHP models
a
Study Vaccine Vaccine
route
Challenge/
route
Level of protection Immune correlates
Beignon
et al. [43]
Lentiviral vector: TRIP-
SIVmac239 gag
subQ SIVmac251/
IR
Reduction of acute viremia T-cell responses in PBMC
Zhao et al.
[44]
DNA/MVA HIV-1
immunogens
IM SHIV162P/
IR
Lower peak and total plasma
vRNA levels
Non-neutralizing but high-avidity
Ab in plasma
Suh et al.
[45]
Multigenic DNA and
recombinant adenovirus
vaccine
IM SIVmac239/
oral
Lower plasma vRNA levels;
prolonged survival
Gag-specific IFN-γ ELISPOT
T-cell responses in PBMC
Sparger
et al. [46]
Δvif SIVmac239 DNA
vaccine boosted with
SIV/CMVΔvif
plasmid DNA
IM SIVmac251/
vaginal
Transient decrease in plasma
vRNA levels; prolonged
survival
SIV-specific T-cell proliferative
responses and antiviral antibody
titers in blood
Dubie et al.
[47]
SIV/CMVΔvif DNA +
(rIL)-15 expression plasmid
IM/ID SIVmac251/
vaginal
Sustained suppression of
plasma virus loads
SIV-specific cellular responses
greater in blood at 12-wk PC
Lai et al.
[48]
DNA/MVA + GM-CSF IM or ID SHIV89.6P/
IR
Lower peak viremia and
virus shedding
High avidity anti-Env IgG in
blood and long-lasting antiviral
IgA in rectal secretions
Cristillo
et al. [49]
DNA boosted with HIV-1
gp120 Env and p41
Transdermal SHIV162P3/
IR
Lower plasma viremia
(4/5 animals)
Gag- and Env-specific central
memory T-cell responses on
the day of challenge
Hansen
et al. [27]
RhCMV vectors expressing
SIV Gag, Rev/Nef/Tat,
and Env
subQ SIVmac239/
IR
Increased resistance to
infection
SIV-specific, TEM responses
and accumulation in lung
Vaccari
et al. [50]
DNA-poxvirus-based
vaccines
IM + ID/IM SIVmac251/
IR
Lower vRNA levels in
mucosal sites; preservation
of mucosal CD4
+ CCR5
+
T cells
Delayed or no expression of
T-cell activation markers in
mucosal sites
Ab antibody; CMV cytomegalovirus; ELISPOT enzyme-linked immunosorbent spot; Env envelope; Gag group-specific antigen; GMCSF
granulocyte-macrophage colony-stimulating factor; ID intradermal; IFN interferon; IM intramuscular; IR intrarectal; MVA modified vaccinia virus
Ankara; Nef negative factor; PBMC peripheral blood mononuclear cell; PC postchallenge; Rev regulator of virion protein expression; RhCMV
rhesus cytomegalovirus; rIL recombinant interleukin; SHIV simian-human immunodeficiency virus; SIV simian immunodeficiency virus; subQ
subcutaneous; Tat trans-activator of tTranscription; TEM effector memory T cells; TRIP triplicate
aDoes not include live-attenuated virus studies
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after vaginal SIV challenge. The results of these studies
demonstrated that SIV Gag-specific CD8
+ T cells in the
vaginal mucosa at the time of SIV challenge are the key
immune effector function mediating protection in this
model [10, 28–30], and that CD8
+ lymphocyte depletion
leaves SHIV-immunized animals completely unprotected
from the vaginal SIV challenge [10, 29]. Despite the
evidence for the critical role of SIV-specific CD8
+ T-cell
responses in SHIV-immunized monkeys, expansion of SIV-
specific CD8
+ T cells is limited to the vaginal mucosa, and
there is minimal immune activation after the SIV challenge
[29]. The extent of host inflammation and immune
activation affects viral transcription directly and determines
the number of target cells available for virus replication.
HIV and SIV replication are regulated by a complex
Fig. 1 Innate and adaptive immune responses in the vagina at the
time of, and immediately after, vaginal SIV inoculation of rhesus
macaques immunized with an attenuated lentivirus compared with the
responses in nonimmunized rhesus macaques. The figure schemati-
cally depicts the vaginal mucosa and the draining lymph node of
SHIV89.6-immunized RMs (a, b) and nonimmunized RMs (c, d)a t
day 0 (a, c) and day 3 (b, d) after SIVmac239 vaginal challenge. In all
panels, nonspecific T cells are gray to black. a SIV-specific CD4
+ T
cells (blue circles) and CD8
+ T cells (red circles) are present on the
vaginal mucosa of immunized RMs on the day of SIV challenge. The
number of IDO
+ APCs (orange) are reduced, and the mRNA levels of
proinflammatory cytokines (C-C motif chemokine 3 [CCL3], CCL20,
and TNF) are reduced, while the mRNA levels of the immunoregu-
latory Siglec-5 molecule are increased. In the genital lymph node,
expression of CCL3, CCL20, IL-8, and IL-17 are also downregulated.
b Three days after challenge, SIV infection is limited to the mucosal
site of challenge in immunized animals. This early containment is
associated with the presence of SIV-specific effector CD8
+ T cells in
the vaginal mucosa and the proliferation of regulatory FOXP3
+ CD4
+
T cells (purple circles) in the mucosa. c In contrast, in nonimmunized
RMs there are no SIV-specific memory effector T cells in the mucosa,
and the levels of proinflammatory or regulatory T cells are normal on
the day of challenge. d However, after the virus enters the mucosa,
local viral replication leads to systemic dissemination, and the level of
infection rapidly exceeds the ability of the immune system to contain
viral replication. The pace of SIV replication accelerates over the first
2 to 5 days of infection, as the rapid increase in local and systemic
proinflammatory cytokines recruits and activates viral target cells in
the vaginal mucosa. APC antigen-presenting cell; FOXP3 forkhead box
P3; IDO indoleamine 2,3-dioxygenase; IL interleukin; LN lymph node;
RM rhesus macaque; SHIV simian-human immunodeficiency virus;
Siglec sialic acid-binding immunoglobulin-like lectin; SIV simian
immunodeficiency virus; TNF tumor necrosis factor
24 Curr HIV/AIDS Rep (2010) 7:19–27network of cytokines and chemokines, as these soluble
factors directly influence reverse transcription, HIV RNA
expression, and expression of viral receptors and corecep-
tors [31–33]. Cytokine and chemokines also regulate
migration and activation of viral target cells, amplifying
HIV infection and replication [31–33]. Thus, both the
strength of the CD8
+ T-cell response and the degree of
immune activation and inflammation can influence the level
of viral replication. After vaginal SIV challenge, immune
activation in the SHIV-immunized animals was controlled
and limited, in contrast to the aberrant T-cell activation in the
unimmunized animals [29]. On the day of SIV challenge, the
antiviral CD8
+ T-cell responses of SHIV-immunized animals
existed in a relatively quiescent tissue environment [28]
(Fig. 1). After SIV challenge, this quiescent tissue environ-
ment was actively maintained by a T-regulatory cell response
that rapidly expanded to suppress any immune activation and
prevent the generation of more activated target cells to
support SIV replication (Genescà and Miller, unpublished
data) (Fig. 1). The decreased levels of proinflammatory
cytokines and indoleamine 2,3-dioxygenase (IDO
+)c e l l si n
SHIV-immunized animals after vaginal SIV challenge are
consistent with immunoregulatory mechanisms playing an
active role in achieving this condition (Genescà and Miller,
unpublished data) (Fig. 1).
Conclusions
The goal of conventional HIV vaccines is to elicit a strong
systemic neutralizing antibody response that can limit
infection upon HIV exposure and CD8
+ T-cell responses
to clear the infection after transmission. To improve the
efficacy of these vaccines against mucosally transmitted
HIV infections, new strategies for directing immune
responses into mucosal sites are needed. Further, as immune
activation and T-cell expansion counter balance the benefits
of strong antiviral mucosal immune responses (Genescà and
Miller, unpublished data), understanding and controlling the
relationship between immune activation and protective
mucosal immune responses may be a critical factor in
developing an effective mucosal AIDS vaccine. An effective
vaccine against HIV will require broadly neutralizing
antibody responses to block infection of new target cells
and antiviral T cells to control viral spread and eliminate
infected cells. However, the results of efficacy trials of
systemic AIDS vaccines suggest that antiviral immune
responses at mucosal surfaces will be required to increase
protection levels in AIDS vaccines. New immunization
routes and adjuvants that can boost antiviral immunity in
mucosal surfaces offer the best hope for improving AIDS
vaccine efficacy in the near term, and NHP models offer the
best system for preclinical evaluation of these approaches.
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